Dianthus expects ~$173M cash at year-end 2023; to present at JPM conference

Dianthus Therapeutics, Inc. /DE/

Preliminary unaudited cash, equivalents, and short-term investments of ~$173M as of Dec 31, 2023.
Audited FY2023 financials not yet available; actual results may differ materially.
CEO Marino Garcia to present at 42nd Annual J.P. Morgan Healthcare Conference on Jan 11, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.